Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non Valvular Atrial Fibrillation Clear all
Completed Not applicable Interventional Results available

Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence

NCT02690649
View directory record Official record
Conditions
Atrial Fibrillation, Medication Adherence
Interventions
Health Messaging (Non-Procedural)
Other
Lead sponsor
Tammy Toscos
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 4, 2026, 8:24 AM EDT
Active, not recruiting Not applicable Interventional

An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation

NCT05565599
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
Left Atrial Appendage Closure
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Tucson, Arizona • Jonesboro, Arkansas • La Jolla, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 8:24 AM EDT
Completed No phase listed Observational

Real-world Dosing Patterns of Rivaroxaban in the United States

NCT03242278
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
12,507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 4, 2026, 8:24 AM EDT
Completed No phase listed Observational Results available

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

NCT03026556
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
42,534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 4, 2026, 8:24 AM EDT
Not listed Phase 4 Interventional

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

NCT03088072
View directory record Official record
Conditions
Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure
Interventions
Edoxaban, WATCHMAN LAA Closure, Aspirin and Clopidogrel, Aspirin and Warfarin
Drug · Device
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 4, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 4, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Results available

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

NCT03061006
View directory record Official record
Conditions
Dementia, Cognition Disorders, Cerebral Ischemic Events
Interventions
Dabigatran Etexilate, Warfarin
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
65 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 4, 2026, 8:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stroke Feasibility Study

NCT01997905
View directory record Official record
Conditions
Atrial Fibrillation, AFib
Interventions
AtriClip LAA Exclusion Device
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
St. Helena, California • Miami, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 4, 2026, 8:24 AM EDT
Completed No phase listed Observational

Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure

NCT03508271
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
65 Years and older
Enrollment
60,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 4, 2026, 8:24 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The CONFORMAL Early Feasibility Study

NCT03616028
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
left atrial appendage closure
Device
Lead sponsor
Conformal Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
11
States / cities
Jonesboro, Arkansas • Santa Monica, California • Manchester, New Hampshire + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 4, 2026, 8:24 AM EDT
Terminated Phase 3 Interventional Results available

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

NCT03839355
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 4, 2026, 8:24 AM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

NCT02690155
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
38,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 4, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Results available

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

NCT02608099
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Interrupted apixaban, Uninterrupted apixaban
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Huntsville, Alabama • Mission Viejo, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 4, 2026, 8:24 AM EDT
Completed No phase listed Observational

Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients

NCT02461602
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Pasadena, California • Coral Springs, Florida • Port Charlotte, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 4, 2026, 8:24 AM EDT
Terminated Phase 3 Interventional Results available

WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

NCT03302494
View directory record Official record
Conditions
Stroke
Interventions
Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device
Device
Lead sponsor
Coherex Medical
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 4, 2026, 8:24 AM EDT
Completed No phase listed Observational

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

NCT04509193
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Warfarin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
116,049 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 4, 2026, 8:24 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Validation of CIRC Technologies

NCT07081711
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrillation, Ventricular Fibrillation
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2037
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 4, 2026, 8:24 AM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

NCT02687854
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
18,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 4, 2026, 8:24 AM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

NCT02687867
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran (Pradaxa), Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 4, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

NCT00262600
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
warfarin, Dabigatran dose 1, Dabigatran dose 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
18,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
374
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 4, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

AMPLATZER™ Amulet™ LAA Occluder Trial

NCT02879448
View directory record Official record
Conditions
Stroke
Interventions
Amulet Left Atrial Appendage Occluder, WATCHMAN Left Atrial Appendage Closure
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
85
States / cities
Huntsville, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 4, 2026, 8:24 AM EDT
Completed Not applicable Interventional

Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm

NCT03515083
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
Alive Cor Kardia mobile electrocardiogram monitor
Device
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 4, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

NCT00742859
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
betrixaban, Warfarin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Anaheim, California • Colorado Springs, Colorado • Melbourne, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 4, 2026, 8:24 AM EDT
Completed No phase listed Observational

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation

NCT03087487
View directory record Official record
Conditions
Non-Valvular Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
466,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 4, 2026, 8:24 AM EDT